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MicroRNA–mRNA interactions underlying
colorectal cancer molecular subtypes
Laura Cantini1,2,3, Claudio Isella1,4, Consalvo Petti4, Gabriele Picco1,4, Simone Chiola1,4, Elisa Ficarra2,
Michele Caselle5 & Enzo Medico1,4
Colorectal cancer (CRC) transcriptional subtypes have been recently identified by gene
expression profiling. Here we describe an analytical pipeline, microRNA master regulator
analysis (MMRA), developed to search for microRNAs potentially driving CRC subtypes.
Starting from a microRNA–mRNA tumour expression data set, MMRA identifies candidate
regulator microRNAs by assessing their subtype-specific expression, target enrichment in
subtype mRNA signatures and network analysis-based contribution to subtype gene
expression. When applied to a CRC data set of 450 samples, assigned to subtypes by
3 different transcriptional classifiers, MMRA identifies 24 candidate microRNAs, in most
cases downregulated in the stem/serrated/mesenchymal (SSM) poor prognosis subtype.
Functional validation in CRC cell lines confirms downregulation of the SSM subtype by
miR-194, miR-200b, miR-203 and miR-429, which share target genes and pathways
mediating this effect. These results show that, by combining statistical tests, target prediction
and network analysis, MMRA effectively identifies microRNAs functionally associated to
cancer subtypes.
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C
olorectal Cancer (CRC) is a major cause of cancer
mortality and is endowed with wide molecular, biological
and clinical heterogeneity. Recently, multiple research
groups have independently identified transcriptional signatures
defining CRC molecular subtypes, endowed with different
biological properties (crypt cell subtype, active pathways),
molecular features (type of genomic instability, oncogenic
mutations and methylator phenotype) and clinical features
(prognosis, response to treatment)1–5. The number of distinct
subtypes identified ranges from three to six, which raised the
question of what are the correlations between the subtypes
defined in the different works. Recently, we provided a unifying
frame to reconcile the different CRC classification systems6. The
consensus partition is composed of three major transcriptional
categories: (1) inflammatory/goblet; (2) TA/enterocyte and
(3) stem/serrated/mesenchymal (SSM). A still pending issue is
which biological mechanisms and regulatory networks underlie
the CRC molecular subtypes. In this context, a key role may be
played by microRNAs, small non-coding RNAs of 20–22
nucleotides that bind complementary sequences in target
mRNAs and thus reduce their stability and translation rate7.
Indeed, several microRNAs have been shown to have altered
expression associated to pro-oncogenic or tumour suppressor
activity in CRC8. In particular, a number of so-called oncomiRs
have been identified for their ability to influence key steps in the
metastatic process and to be involved in circuits-regulating
epithelial to mesenchymal transition (EMT), a critical step that
drives tumour metastasis. It is therefore reasonable to hypothesize
that some microRNAs may have a driving role on the CRC
transcriptional subtypes. Identification of such microRNAs
requires integrative analysis of paired microRNA–mRNA
expression profiles from a large set of CRC samples. Recently,
integrative computational methods have been proposed to
discover microRNA–mRNA interactions possibly involved in
tumour development8,9. However, these methods have been
typically applied to distinguish tumour from normal tissue, a
comparison characterized by much wider variation than between
two tumour subtypes. Moreover, the methods only take into
account microRNA–mRNA interactions supported by anti-
correlation, while it has been recently observed that microRNAs
can act also indirectly through, for example, regulation of
silencing complexes10. Finally, the above methods do not
prioritize the identified microRNA–mRNA interactions.
To overcome all these limitations, we propose the microRNA
master regulator analysis (MMRA) analysis pipeline, aimed at
discovering which microRNAs potentially regulate which CRC
subtype. MMRA is subdivided in four sequential steps, each
aimed at progressively reducing the number of candidate
microRNAs: (i) differential expression analysis to highlight
microRNAs with subtype-specific expression; (ii) target transcript
enrichment analysis, to further select those microRNAs whose
predicted targets are enriched in the associated subtype mRNA
signature; (iii) network analysis, in which an mRNA network is
constructed around each microRNA using ARACNE (ref. 11),
and tested for enrichment in signature genes; (iv) identification of
microRNAs whose expression ‘explains’ the expression of subtype
signature genes, using stepwise linear regression (SLR) analysis12.
An overview of the workflow and of the algorithmic steps is
provided in Fig. 1. Here MMRA is first applied to CRC samples
subdivided by their microsatellite instability status, where it
promptly identifies microRNAs known to be associated with
this molecular phenotype. MMRA is then applied to a paired
mRNA–microRNA expression data set of 450 CRC samples
whose transcriptional subtype, according to three different
classifiers, is already established6. In this data set MMRA
identifies several microRNAs whose increased expression is
associated with downregulation of SSM subtype genes.
MicroRNA–mRNA associations involved in subtype determi-
nation are confirmed in a CRC cell line mRNA–microRNA
expression data set, and functionally validated by microRNA
silencing experiments in vitro. These results show the
efficacy of MMRA in identifying microRNAs functionally
associated to cancer subtypes, with diagnostic and therapeutic
implications.
Results
Expression data set assembly and preliminary tests. For this
study, we obtained CRC microRNA expression data from The
Cancer Genome Atlas (TCGA), and generated a matched
mRNA–microRNA expression data set by integrating mRNA
expression data that we previously assembled from TCGA6 for
the same samples. Transcriptional classification of the samples
according to the three above mentioned classifiers, dubbed colon
cancer subtypes (CCS1), CRC-assigner (CRCA2) and colon
cancer molecular subtypes (CCMS3) was obtained from
Supplementary Table 1 of Isella et al.6 Notably, all three
signatures classify the large majority of the TCGA samples with
high statistical confidence (false discovery rate (FDR)o5%): 94%
for CCMS, 90% for CRCA and 74% for CCS. However, definition
of the optimal transcriptional classification of CRC into
molecular subtypes is still an ongoing process, which brings
some degree of uncertainty about the underlying mRNA–
microRNA networks. To test MMRA on an unambiguous
STEP 2: 
microRNA target 
enrichment analysis
MicroRNAs whose 
predicted targets are 
enriched in subtype 
signature genes
STEP 1: 
microRNA differential
expression analysis
OutputProcedure
MicroRNAs with
subtype-specific 
expression
STEP 3:
network analysis
Results: 
microRNAs with subtype-specific expression
significantly contributing to the expression
of subtype signature genes.
MicroRNAs whose 
mRNA ‘regulon’ is 
enriched in subtype 
signature genes
STEP 4: 
stepwise linear 
regression analysis
MicroRNAs contributing 
to the expression of 
subtype signature 
genes
Data: 
1. Paired microRNA/mRNA expression data set
2. Classification of the samples into subtypes
3. Subtype-specific mRNA expression signatures
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respective outputs, and the final output of the pipeline.
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phenotype, we applied it to CRC samples subdivided by their
microsatellite instability status, which was available for 280
samples of the data set. As MMRA uses in steps (ii–iv) a possibly
independent mRNA signature distinguishing sample subgroups,
we adopted a published signature composed of 53 mRNAs
upregulated in microsatellite stable (MSS) samples and 11
mRNAs upregulated in microsatellite instable (MSI) samples13.
MMRA identified three microRNAs potentially regulating the
MSI/MSS transcriptome, two upregulated in MSS (miR-196b and
miR-106a) and one upregulated in MSI samples (miR-31).
Indeed, the role of all three microRNAs in regulating the MSI/
MSS phenotype is well documented and in accordance with our
findings14–16, which confirms the validity of the approach.
Application of MMRA to CRC transcriptional subtypes. The
first step of the pipeline consisted of finding microRNAs with
subtype-specific expression. The results are summarized in
Supplementary Data Set 1. In particular, we detected 52
microRNAs differentially expressed across CCS subtypes, with a
FDR of 0.1%, 59 across CRCA subtypes (FDR¼ 0.2%) and 54
across CCMS subtypes (FDR¼ 0.7%). The analysis revealed a
considerable overlap in differential microRNAs (Supplementary
Fig. 1): 44 microRNAs displayed subtype-specific expression in all
3 classifiers, and only 11 were significant for just 1 classifier. Such
a wide overlap suggested that specific subtypes from the various
classifiers do indeed share the same upregulated or down-
regulated microRNAs. To provide a unified view of subtype-
specific microRNA expression across all three classifiers, and
possibly build a microRNA-based subtype consensus, we selected
all the microRNAs differentially expressed in at least one subtype
of at least one classifier (in total, 66 microRNAs). We then
computed 14 centroids, considering the mean expression of these
microRNAs in each subtype of each classifier (CRCA 1–5, CCS
1–3 and CCMS 1–6). To this centroid matrix we applied a con-
sensus hierarchical clustering with P values (pvclust R package17).
The resulting hierarchical tree (Fig. 2a and Supplementary Fig. 2)
highlighted a first subdivision between SSM and non-SSM
centroids with a confidence 495%. The non-SSM centroids
were then further partitioned in two subgroups: TA/enterocyte
and inflammatory/goblet. These results are in complete
accordance with our previous subtype reconciliation based on
mRNA expression6, highlighting a strong correlation between
mRNA- and microRNA-based transcriptional classification of
CRC. Figure 2 shows expression of the 66 microRNAs in CRC
subtypes assigned by the 3 classifiers, organized by the
hierarchical subtype consensus. MicroRNA clustering by
their expression across all samples highlighted four major
classes, respectively (i) upregulated in inflammatory/goblet;
(ii) upregulated in TA/enterocyte; (iii) upregulated in SSM; and
(iv) downregulated in SSM. The size of the clusters clearly shows
that most of the microRNAs are differentially expressed between
SSM and non-SSM subtypes.
In the second step of the pipeline, 31 of the 66 subtype-specific
microRNAs were found to also have their predicted targets
enriched in genes of the corresponding subtype mRNA signature
(some of them in more than 1 signature and/or more than 1
classifier). The results of this step are reported in Supplementary
Table 1. In the third MMRA step, a ‘regulon’ (a single-hub
network of significant interactions) was first constructed around
each of the 31 selected microRNAs using the paired mRNA
expression data set (see Methods section). The number of links in
the obtained regulons varied widely, from 17 to 1,492 mRNAs,
however being between 300 and 600 in the majority of the cases.
In each regulon, mutual information (MI) values were almost
invariably between 0.11 and 0.4. Details are reported in
Supplementary Table 2. Subsequently, the 31 regulons were
tested for enrichment in subtype signature genes. As a result, only
one microRNA was filtered out, confirming a good correspon-
dence between the subtype-based analysis of steps i and ii, and the
unsupervised network-based approach of step iii. Remarkably, in
some cases, signature genes were not only enriched in the
regulons, but also, within the regulon, were among those with the
highest MI values. Figure 3 reports four such cases (miR-194,
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Figure 2 | Subtypes consensus clustering applied to differentially
expressed microRNAs in TCGA data set. (a) Consensus hierarchical
clustering of 14 subtype centroids (CRCA 1–5, CCS 1–3 and CCMS 1–6).
Each centroid was calculated by averaging, for each of 66 microRNAs
differentially expressed in at least one subtype, expression in the samples
assigned to the subtype. The dendrogram shows a subdivision of the
subtype centroids in three major subgroups: SSM (blue), TA/enterocyte
(red) and inflammatory/goblet (green). (b–d) Heatmaps displaying the
expression of the 66 subtype-specific microRNAs in samples subdivided by,
respectively, the CRCA (b), CCMS (c) and CCS (d) classifiers. MicroRNAs
are subdivided by fuzzy self-organizing maps in four expression clusters
with differential expression across the three consensus subgroups.
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miR-429, miR-141 and miR-181d). A summary of all the results
of this step is reported in Supplementary Table 3. The fourth step
of MMRA further restricted the candidate microRNAs to 24
whose expression was found to fit the expression of subtype
signature genes included in their regulons, according to SLR
analysis12,18. For the majority of them (20) expression of the
microRNA was opposite to that of the associated gene signature,
while the remaining 4 had concordant expression.
The final output of the MMRA pipeline is reported in Table 1.
Interestingly, 16 out of the 24 identified microRNAs were
negatively associated to the SSM subtype: they had lower
expression in CCMS4, CRCA5 and CCS3 samples and were
associated by the pipeline to genes upregulated in the same
subtypes. Therefore, most of the MMRA-identified microRNAs
are likely regulating a more generic ‘SSM/non-SSM’ subdivision,
rather than driving single subtypes. This result is in line with the
major bifurcation observed between SSM and non-SSM samples
described in Fig. 2.
Validation of microRNA-subtype associations in cell lines. We
recently found that genes whose expression is positively asso-
ciated with the SSM subgroup of CRC are mostly expressed by
stromal cells6. Nevertheless, in an expression data set of 151 CRC
cell lines, we detected the SSM subtype with confidence in about
15% of the cases19. This indicates that in some cases CRC
neoplastic cells do indeed undergo epithelial–mesenchymal
transition and display stem cell-like features, and that
exploiting mRNA–microRNA interactions may help
distinguishing cancer cell-intrinsic features from stromal
contribution. Therefore, to test whether microRNA–mRNA
interactions highlighted by the pipeline hold true also
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Figure 3 | CRC subtype signature genes have high MI with specific microRNAs. The figure reports GSEA analysis of CRC subtype signatures within
selected microRNA regulons, as indicated on top of each panel. The signatures were selected among those enriched in genes contained in the regulon.
Within each of the indicated microRNA regulons, genes are sorted by decreasing MI with the microRNA, from left to right. The enrichment plots show that
the displayed signatures are also enriched in genes with particularly high MI with the microRNA within the regulon.
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in the absence of stromal cells, we assembled a paired
mRNA–microRNA expression data set consisting of 18 CRC
cell lines for which we had generated both mRNA and microRNA
expression profiles. To test microRNA differential expression
across subtypes, we took advantage of our previous subtype
assignment for the 18 cell lines19. Considering subtype-specific
expression, almost all microRNAs identified by the MMRA
pipeline agreed in cell lines with the upregulation or
downregulation observed in the TCGA data set (11/13 in
CCMS, 16/19 in CRCA and 2/2 in CCS), confirming the
reliability of the cell lines as model for the transcriptional
subtypes. We then performed a more stringent analysis of
microRNA-subtype association in CRC cell lines, for which
validated microRNAs had to fulfil two conditions: (i) TCGA-
concordant differential expression of the microRNA between cell
lines of the target subtype and all other cell lines, beyond a
significance threshold of 1.321722 for CCMS, 1.237681 for CRCA
and 1.521026 for CCS; (ii) significant fraction of subtype
signature genes (5% for CCMS and 10% for CRCA) whose
expression is correlated (positively or negatively) to the
microRNA across subtypes. More details are provided in
Methods section. MicroRNA/subtype association were
maintained in cell lines according to both criteria for 7 (30%)
of the 24 microRNAs. The fraction of validated associations
increased to 38% (5 of 13) for those considering only the CCMS
classifier, for which subtype gene signatures have the largest size.
Considering validation in cell lines, MMRA was found to be
substantially more reliable than alternative pipelines developed to
detect microRNA–mRNA interactions dysregulated in cancer
versus normal tissue8,9. Similarly, simpler, less computationally
intensive versions of the MMRA pipeline gave less reliable results.
More details about these comparisons, including tests of
validation in independent data sets, are provided in
Supplementary Note.
MicroRNA functional validation in cell lines. To functionally
validate the identified associations between microRNAs and CRC
subtypes, we prioritized three cell lines in which, based on mRNA
and microRNA expression data, downregulation of specific
microRNAs that are upregulated in non-SSM samples should
result in a transcriptional shift towards the SSM subtype. In
particular, NCIH508 cells were selected for validation of four
microRNAs (miR-194, miR-200b, miR-203 and miR-429), HT29
cells for three microRNAs (miR-194, miR-200b and miR-429)
and SW403 cells for miR-429. Details about the procedures used
for microRNA and cell line prioritization are provided in
Methods section. Cells were transduced with lentiviral
vectors carrying microRNA-targeting sequences (‘miRZIPs’) to
downregulate expression of each individual microRNA. After
Table 1 | MicroRNAs identified by MMRA with differential expression across CRC subtypes and associated to subtype-specific
mRNA signatures.
MicroRNA MicroRNA expression Associated subtype signature SLR-estimated association (%) Other associated subtype signatures
hsa-miR-223 Up in CRCA1 Down in CRCA1 15 CRCA-UP4
hsa-miR-181d Down in CRCA1 Up in CRCA1 21 CRCA-DN4
hsa-miR-375 Up in CRCA2 Down in CRCA2 14 —
hsa-miR-103 Down in CRC5 Up in CRCA5 30 CRCA-DN2þDN3þDN4
hsa-miR-130b Down in CRCA5 Up in CRCA5 37 CRCA-UP1þDN2þDN3þDN4
hsa-miR-135b Down in CRCA5 Up in CRCA5 14 —
hsa-miR-141 Down in CRCA5 Up in CRC5 24 CRCA-DN2þDN3
hsa-miR-143 Up in CRCA5 Up in CRC5 14 CRCA-DN2
hsa-miR-148a Down in CRCA5 Up in CRCA5 30 CRCA-DN2þDN3þDN4
hsa-miR-153 Down in CRCA5 Up in CRCA5 19 CRCA-DN2þDN3
hsa-miR-17 Down in CRCA5 Up in CRCA5 24 CRCA-DN2þDN3þDN4
hsa-miR-194 Down in CRCA5 Up in CRCA5 16 CRCA-DN2
hsa-miR-19b Down in CRCA5 Up in CRCA5 20 CRCA-DN2þDN4
hsa-miR-200b Down in CRCA5 Up in CRCA5 24 CRCA-DN2þDN3
hsa-miR-203 Down in CRCA5 Up in CRCA5 21 CRCA-DN2
hsa-miR-20a Down in CRCA5 Up in CRCA5 29 CRCA-UP1þDN2þDN4
hsa-miR-429 Down in CRCA5 Up in CRCA5 20 CRCA-DN2
hsa-miR-33a Down in CRCA5 Up in CRCA5 24 CRCA-DN2þDN4
hsa-miR-218 Up in CRCA5 Up in CRCA5 25 CRCA-DN2þDN3þDN4
hsa-miR-141 Down in CCS3 Up in CCS3 31 CCS-DN1
hsa-miR-200a Down in CCS3 Up in CCS3 15 —
hsa-miR-501 Up in CCMS1 Down in CCMS1 18 CCMS-DN3þUP4
hsa-miR-141 Down in CCMS4 Up in CCMS4 21 CCMS-DN1þDN3
hsa-miR-148a Down in CCMS4 Up in CCMS4 24 CCMS-DN1þDN3þUP5
hsa-miR-153 Down in CCMS4 Up in CCMS4 15 CCMS-DN1þDN3
hsa-miR-200a Down in CCMS4 Up in CCMS4 15 CCMS-DN1þDN3
hsa-miR-33a Down in CCMS4 Up in CCMS4 23 CCMS-DN1þDN3
hsa-miR-130b Down in CCMS4 Up in CCMS4 28 CCMS-DN1þDN3þUP5
hsa-miR-194 Down in CCMS4 Up in CCMS4 14 —
hsa-miR-362-3p Down in CCMS4 Up in CCMS4 28 CCMS-DN1þDN3þUP5
hsa-miR-429 Down in CCMS4 Up in CCMS4 15 CCMS-DN1þDN3
hsa-miR-203 Down in CCMS4 Up in CCMS4 20 CCMS-DN1þDN3
hsa-let-7c Up in CCMS4 Up in CCMS4 22 CCMS-DN1þDN3
hsa-miR-1-2 Up in CCMS4 Up in CCMS4 14 CCMS-DN1þDN3
The table reports the MMRA pipeline output. The first column reports the identified microRNAs, the second column the subtype in which the microRNA is differentially expressed and if it is upregulated
or downregulated. The third column reports the gene signature associated to each microRNA. The fourth column reports the percentage of signature genes whose expression is recapitulated by the
microRNA expression in SLR analysis. The rightmost column reports other subtype signatures of the same classifier associated with the microRNA by SLR analysis.
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selection of stably transduced cells, microarray-based mRNA
expression profiling was conducted to evaluate transcriptional
changes. In accordance with the above-described subtype
consensus and MMRA output, we considered only two major
cellular states: SSM and non-SSM. To obtain two complementary
gene signatures for this partition, we grouped together on one
side all the SSM-UP subtype signatures, and on the other all the
SSM-DOWN subtype signatures (details are reported in Methods
section). Two tests were made to prove the driver role of the four
microRNAs: (i) enrichment analysis of SSM-UP/DOWN
signature genes within the sets of genes that were upregulated or
downregulated on microRNA silencing; and (ii) assignment of the
transduced versus control cell lines to the SSM- or non-SSM
classes using nearest template prediction (NTP)20, a class
prediction algorithm with confidence assessment that we
previously used to classify CRC samples and cell lines6,19. The
results of the tests are summarized in Table 2. Details about gene
modulation after mirZIPs transduction are provided in
Supplementary Data Sets 2–4, respectively, for HT29, NCIH508
and SW403 cell lines. Remarkably, as hypothesized, silencing of
the selected microRNAs induced a detectable transcriptional shift
towards the stem-like state in all cases. In particular, genes
upregulated by mirZIPs were significantly enriched in SSM-UP
genes in seven out of eight cases, and genes downregulated by
mirZIPs were significantly enriched in SSM-DOWN genes in five
out of eight cases, with at least one of the two enrichment tests
significant in all cases. Moreover, in all cases but one, mirZIP
transduction led to NTP-based reassignment of the cells to the
SSM subtype with confidence. A possible explanation for the only
exception is that SW403 cells are strongly non-SSM. Therefore,
despite a strong significance of both SSM-UP and SSM-DOWN
enrichment analyses, they failed to reprogram to the SSM
phenotype.
To identify the signalling pathways modulated in cell lines on
silencing of the various microRNAs by their respective mirZIPs,
we applied gene set enrichment analysis (GSEA)21 to the whole
set of expressed genes ranked by their differential expression in
mirZIP-transduced versus control cells. When a mirZIP was used
in more than one cell line, differential expression values were
averaged. The same GSEA analysis was also applied to the above-
described SSM-UP signature, to verify enrichment of upregulated
genes in a threshold-independent manner. The results of this
analysis are displayed in Fig. 4 and Supplementary Table 4. Each
of the four mirZIPs led to a positive enrichment score for the
SSM-UP subtype signature, confirming the ‘anti-SSM’ activity of
all four microRNAs. Moreover, while most functions were
specifically modulated by single microRNAs, upregulation of
genes involved in ‘TNF signalling pathway via NFkB’ was
promoted by downregulation of three microRNAs (miR-194,
miR-200b and miR-429). Interestingly, downregulation of miR-
203 on one side induced genes of the ‘TGF-b pathway via SMAD
activation’, and on the other repressed cell cycle genes (‘E2F
Targets’ and ‘G2M checkpoint’). It is therefore likely that miR-
203 indirectly promotes cell cycle by downregulating TGF-b
pathway genes. ‘MYC targets’ and EMT markers (‘Epithelial
Mesenchymal Transition’ and ‘NABA ECM regulators’) were
upregulated on silencing of, respectively, miR-194 and miR-200b.
miR-429 is likely to have an immunosuppressive function, since
its downregulation was found to promote expression of genes
involved in inflammation (‘Interferon Gamma Response’ and
‘Inflammatory Response’).
Identification of core microRNA predicted targets. To single
out potential mediators of the anti-SSM action of the four
validated microRNAs, we defined a set of key genes (‘core
targets’) associated with each microRNA according to both
in vitro and in vivo observations. In particular, a core target of a
microRNA should: (i) be significantly in vitro upregulated on
silencing of a given microRNA, as described above; (ii) have a
negative association coefficient with the same microRNA
expression in human CRC samples, as determined by SLR
analysis in the TCGA expression data set, considering each
selected gene as response variable and the four functionally
validated microRNAs as explanatory variables. According to this
procedure, 22 core targets were found for miR-194, 18 for
miR-200b and 10 for miR-429. No core targets were found for
miR-203, likely because the significantly modulated genes in vitro
by its downregulation were only three. However, SLR analysis,
carried out on all four microRNAs for all in vitro upregulated
genes, highlighted negative association with miR-203 for eight
core targets of other microRNAs. A similar cross-association was
also observed between the other microRNAs. In total, 21 genes
were associated to more than 1 microRNA, with 2 genes
(EMP1 and PTRF) being core targets of 3 microRNAs. Figure 5
displays the whole network of microRNA–mRNA interactions,
with colour codes depicting involvement in the SSM subtype
and/or functional pathways. The abundant cases of multiple
gene/microRNA connections can be explained by the fact that all
four microRNAs are predicted to control the same phenotypic
subdivision (SSM versus non-SSM). Of note is that miR-194,
miR-200b core-targets seem to be more strongly involved in the
Table 2 | MicroRNA downregulation in CRC cell lines leads to modulation of SSM subtype genes and change in subtype
assignment.
Cell line HT29 NCIH508 SW403
Targeted microRNA mir-194 mir-200b mir-429 mir-194 mir-200b mir-429 mir-203 mir-429
Upregulated genes (total) 252 567 163 20 6 20 32 104
Fold enrichment in SSM genes 5.23 3.01 2.85 5.9 19.7 59.2 33.3 7.55
Enrichment P value 2.4E-08 2.9E-06 1.4E-02 0.14 0.049 2.2E-16 3.8E-12 0.0001
Downnregulated genes (total) 244 411 115 6 1 2 11 83
Fold enrichment in non-SSM genes 6.65 1.67 0.54 8.8 0 5.9 1.8 4.4
Enrichment P value 1.6E-14 0.034 0.29 9.3E-05 0.983 2.9E-04 0.158 0.002
Original subtype SSM Non-SSM Non-SSM
Original FDR 0.88 0.28 0.002
New subtype SSM SSM SSM SSM SSM SSM SSM Non-SSM
New FDR 0.200 0.001 0.005 0.004 0.005 0.004 0.002 0.002
The table reports, for each cell line and each targeted microRNA, the total number of genes upregulated and downregulated after microRNA silencing, the enrichment of SSM genes among upregulated
genes and of non-SSM genes among downregulated genes, and classification of the cell line into SSM or non-SSM subtype before and after microRNA silencing with the respective classification
confidence expressed as FDR.
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TNF pathway regulation. Moreover genes belonging to SSM
signature or at least strongly upregulated in the SSM subtype are
among those genes with an higher degree in the network (2–3),
showing a combined regulation of the SSM associated genes by all
the four microRNAs.
Discussion
The wide molecular and clinical heterogeneity of CRC-prompts
research aimed at defining more homogeneous subtypes of the
disease. Among the possible ways to achieve this goal, definition
of subtypes based on distinctive transcriptional profiles recently
emerged as a powerful approach1–3. However, no mechanistic
explanation has been provided to justify the different
transcriptional make up of the various subtypes. In this work,
we explored the possible role of microRNAs, by developing and
applying an analysis pipeline, MMRA, aimed at identifying
microRNAs with a potential ‘master regulator’ role.
The MMRA pipeline has multiple innovative features. It works
on large data sets of paired mRNA–microRNA expression, in
which samples are subdivided in two or more subgroups based on
mRNA signatures. It integrates statistics and network theory in
two serially combined analysis modules that, in principle, could
also be used independently. However, the network analysis
module, that we found to improve accuracy of the analysis, could
not be employed in the absence of the microRNA filtering
provided by the statistics module, due to excessive computational
demand. MMRA also makes an original use of the well-known
ARACNE algorithm, employing MI to reconstruct mixed
mRNA–microRNA regulatory networks, the ‘regulons’. Indeed,
existing tools use MI for integrative analysis of microRNA-targets
expression profiles22,23, but they do not use ARACNE for
network reconstruction. In another case, a pipeline built to
identify microRNA-transcription factor networks in
Glioblastoma includes ARACNE, but only to define gene–gene
interactions, while microRNA–gene interactions are identified
through TargetScan24. Therefore ARACNE has never been
applied to mixed mRNA–microRNA data as in MMRA. The
above features and findings establish the MMRA pipeline as a
first-in class tool to successfully combine multiple computational
approaches to find driver microRNAs within paired
mRNA–microRNA expression data sets.
MMRA was applied to a large paired mRNA–microRNA data
set of CRC samples and highlighted the involvement of candidate
microRNAs in regulating CRC subtypes. Notably, most
candidates were predicted to downregulate genes of the poor
prognosis SSM subtype. In vitro functional validation
experiments confirmed the reliability of the pipeline and the role
of miR-194, miR-200b, miR-429 and miR-203 in the negative
regulation of this subtype. Interestingly, these miRNAs inhibit
metastasis through negative regulation of two key biological
properties: EMT and stemness. In fact, several lines of
evidence suggest a connection between metastasis induction
and stem-like properties acquisition from cancer cells undergoing
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EMT25–27. The same link between EMT and stemness is observed
for the four identified microRNAs: they all are inhibitors of the
cancer stem cell phenotype26,28 and are EMT repressors. In
particular miR-200b and miR-429, both part of miR-200 family,
are involved in a feedback regulatory loop with zinc finger
E-box-binding factors ZEB1 and ZEB2, which ensures a switch-
like regulation of EMT27,29. Moreover, miR-194 and miR-203 are
repressed by ZEB1 (refs 26,30). Involvement of the four
microRNAs in EMT was also confirmed by the GSEA analysis
applied to identify signalling pathways modulated in cell lines on
silencing of each microRNA by its respective mirZIP. This
analysis highlighted a consistent and possibly cooperative effect of
all four microRNAs in modulating multiple EMT pathways: TNF
via NFkB signalling, TGF-b pathway, EMT marker genes and
MYC targets. TNF signalling via NFkB is required in cancer cells
to maintain a mesenchymal phenotype31–34. Involvement of
miR-203 in the regulation of TGF-b pathway was already
experimentally observed35 and the role of TGF-b pathway in
EMT is well known36–38. Finally, MYC is involved not only in
EMT but also in cell pluripotency acquisition working as a
connection between stemness and EMT39–41. In particular, MYC
plays a dominant role in regulating several miRNAs in the
reprogramming process to stemness penothype41,42. Our
functional validation highlighted regulation of c-MYC and its
targets on silencing of miR-194, not previously reported as a
MYC-regulated microRNA. Cooperation of the above
microRNAs in driving a non-SSM phenotype is further
substantiated by the finding of a consistent fraction of shared
core mRNA targets, as illustrated in Fig. 5.
We recently showed that a large fraction of genes over-
expressed in SSM samples of CRC are indeed expressed by
stromal rather than cancer cells6. This poses the question of
whether the microRNA–mRNA associations identified by
MMRA, where the target mRNAs are upregulated in SSM
samples, reflects tumour–stroma interactions rather than cancer
cell-intrinsic regulatory circuits. We therefore exploited our
previous analyses6 to verify whether the identified core target
genes are expressed by stromal cells. Estimate of stromal
contribution was available for 38 of the 45 identified core
targets. Interestingly, none of them had an estimated stromal
contribution above 50%, only 9 of 25–50% and 29 had o25%
estimated stromal contribution. These result confirm the power of
an analysis based on microRNA–mRNA interactions detected
both in vitro and in vivo to highlight regulatory circuits mostly
occurring in cancer cells.
Of particular importance is therefore the in vitro validation of
the driver role of of miR-194, miR-200b, miR-429 and miR-203
in bringing CRC cells away from the SSM state. Despite the
change of sampling material (cell lines versus human CRC tissue)
and the limited number of cell lines available for the paired
mRNA–microRNA analysis, the negative relationship between
expression of these microRNAs and SSM subtype was confirmed.
Moreover, experimental downregulation of these microRNAs
caused a detectable shift of the CRC cell mRNA transcriptome
towards the SSM state, even though only one microRNA at a time
was silenced. These results show that the integrative approach
combining supervised statistics with unsupervised network
analysis, at the basis of our MMRA pipeline, allowed reliable
detection of microRNAs with a driving role in determining
molecular and biological features of CRC.
Methods
Pre-processing TCGA microRNA expression data set assembly. To
generate a matched mRNA–microRNA expression data set of primary CRC,
we started from our previously assembled 450-sample TCGA mRNA
data set6, available as ExperimentData package from Bioconductor:
http://www.bioconductor.org/packages/release/data/experiment/html/
TCGAcrcmRNA.html. For all these samples, in April 2013 we downloaded
from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/) level 3 microRNA
expression data generated by small RNA sequencing corresponding to the
‘microRNA.txt’ file. Level 3 small RNAseq data are preprocessed by TCGA as
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described43. Indeed, data processing methods alternative to those employed by
TCGA could provide different results, as discussed by Dillies et al.44, but this would
require direct access to sequence reads. Downloaded data were initially assembled
into two matrices, one for the ‘GA’ platform (229 samples) and one for the ‘Hiseq’
platform (221 samples). No sample was profiled through both platforms, but the
two data sets had an identical distribution. We therefore filtered out those
microRNAs having a s.d. equal to zero (that is, not detected) and those with an
absolute spearman correlation with the GA versus Hiseq platform 40.65 (90th
percentile of the distribution). Finally, we combined the two microRNA data sets
into a unique set providing expression values for 434 microRNAs in 337 colon and
113 rectal adenocarcinomas. The data set is available as ExperimentData package
from Bioconductor:
http://www.bioconductor.org/packages/release/data/experiment/html/
TCGAcrcmiRNA.html. Classification of the TCGA samples in transcriptional
subtypes according to the CCS, CRCA and CCMS classifiers were obtained from
Supplementary Table 1 of Isella et al.6 At the end of this processing step, we had all
the necessary data for the MMRA pipeline: (i) paired mRNA–microRNA
expression data; (ii) samples subdivision by transcriptional classifiers.
Availability of the MMRA pipeline. MMRA is available at http://eda.polito.it/
MMRA/, It is subdivided into four major steps described in the following sections.
MMRA step 1–microRNAs differential expression analysis. The aim of the
first step was to identify microRNAs with subtype-specific expression. To perform
differential microRNA expression analysis, we organized samples according to
their available mRNA-based classification6. Then we defined ‘subtype core’ samples
by restricting subtype membership to those samples that, according to NTP, in
addition of having FDRo5% (standard threshold for the NTP algorithm), also had
a distance from the nearest template (d) o0.8. This value corresponds to the 95th
percentile of the distribution of the distances of all samples from all centroids. The
distance threshold was added to strictly select those samples that are strongly
associated to the class, avoiding the introduction of noise in the differential
expression analysis. The number of core samples defined with the above procedure
is the following: CCS (150, 67, 87), CCMS (18, 54, 42, 82, 65, 54) and CRCA
(50, 40, 42, 94, 70). Although not perfectly balanced, the size of each subtype core
remains comparable. In the analysis, a subtype-specific microRNA should have
significant differential expression between core samples of a given subtype and all
other samples, excluding from the analysis those samples assigned to the test
subtype but with low confidence. Differential expression analysis was performed
through a Kolmogorov–Smirnov test, including a fold-change (FC) threshold.
Kolmogorov–Smirnov test was chosen because it does not assume a priori any data
distribution and its use for differential expression analysis is well documented45,46.
To address the possible issue of sample size, we took advantage of a Kolmogorov–
Smirnov test with bootstrapping (function ks.boot implemented in the R package
‘Matching’47). A microRNA was considered differentially expressed in a subtype if
the Kolmogorov–Smirnov P value was o0.001 and the absolute FC was 42. The
adequacy of the selected thresholds was assessed by a permutation-based estimate
of the FDR, that is, the estimated percentage of microRNAs identified by chance.
For each pair of chosen Kolmogorov–Smirnov P value and FC thresholds, the FDR
was computed reshuffling 1,000 times the samples constituting the microRNA data
set. The mean value of microRNAs significantly differentially expressed in these
1,000 experiments was computed and then compared with the number of
microRNAs differentially expressed in our step of the pipeline. As shown in
Supplementary Table 5, the FDR obtained for the selected pair of thresholds
(P value 0.001, FC 42) was the minimum among all tested combinations in CCS
and CRCA classifiers. For what concerns CCMS, as can be observed from
Supplementary Table 5, the global FDR initially decreases from 6 to 3% and then to
around 1%, finally stabilizing around 0.8–0.6%. It follows that, according to the
global FDR value, all the three combinations ‘0.001–1.5 ’, ‘0.001–2 ’ and
‘0.001–2.5 ’ can be in principle considered very good (FDR o1%). It should be
considered that microRNA differential expression analysis corresponds to the first
step of the MMRA pipeline, therefore the threshold combination should be
sufficiently selective but at the same time not too stringent. For this reason, of the
three tests with FDR o1% we considered the intermediate option ‘0.001–2 ’,
corresponding to 54 microRNAs, as the preferred choice. The other two threshold
choices would lead to 24 or 143 microRNAs over 475, possibly too stringent or not
sufficiently selective. We therefore checked what would change in the results of
MMRA using for differential expression the combination ‘0.001–2.5 ’
corresponding to the minimum FDR. The ‘0.001–2.5 ’ combination yields only
four microRNAs at the end of the pipeline, of which only one is confirmed in cell
lines (25% versus 38% in our chosen test). Importantly, this configuration would
miss miR-194 and miR-429, that were functionally validated by loss-of-function in
cell lines. We also verified the possible changes in the list of differentially expressed
miRs without using the distance from the class centroid to select subtype core
samples. The results confirmed our hypothesis: despite the presence of more
samples per subtype, the resulting set of differentially expressed microRNAs was
smaller, highlighting greater within-subtype heterogeneity. Moreover, the resulting
microRNAs were all contained in the previous list based on subtype cores.
MMRA step 2–target transcripts enrichment analysis. In the second MMRA
step, for each microRNA differentially expressed in a given CRC subtype, we
performed a target enrichment analysis in the gene signature corresponding to the
CRC subtype in which the microRNA was differentially expressed. MicroRNA’s
target transcripts were predicted following the procedure discussed in Riba et al.48
More precisely, we combined the results of four prediction databases (miRTarBase
2.5 (ref. 49), doRiNA-PicTar 2012 (ref. 50), microRNA.org 2010 (ref. 51), PITA
2007 (ref. 52) and TargetScan 6.1 (ref. 53)), requiring the agreement of at least two
of them to include a putative target in our analysis. For each database we always
chose the most stringent option among those proposed by the database. Then we
added to this list all the experimentally validated targets contained in the
miRTarBase 2.5 database. Next, to perform target enrichment analysis and all the
further pipeline steps, the gene signatures CCS, CRCA and CCMS were
downloaded from the Supplementary Materials of the works1–3. Then the genes of
the three classifiers were organized as follows. For each of the CRCA and CCS
subtypes, we defined two gene signatures: the first, that we called ‘UP’, containing
all the genes with prediction analysis of microarray values 40, and the second,
‘DOWN’, containing all the genes with prediction analysis of microarray valueo0,
as reported in the Supplementary Tables of the works. For each CCMS subtype we
selected, as UP genes, those with log2 FC40.5 and adjusted P valueo0.05, and as
DOWN genes those with log2 FC o 0.5 and adjusted P value o0.05. The FC
and P value thresholds are the same as originally used by the authors3. For each
microRNA identified in step (i) as differentially expressed in a given CRC subtype,
to evaluate an enrichment of predicted targets in the UP or DOWN signature of
that subtype, we calculated a Bonferroni-adjusted Hypergeometric test P value and
the observed/expected (O/E) ratio. To choose optimal P value and O/E ratio
thresholds, we implemented a FDR computation as follows. For each subtype, a
random set of microRNAs, of the same size of the subtype-specific microRNA set,
is selected and tested for target enrichment in the UP or DOWN signatures of the
same subtype, according to a given combination of P value and O/E ratio
thresholds. After 1,000 random iterations, the mean number of randomly
significant microRNAs across a classifier is compared with the number of ‘true’
significant microRNAs for the same classifier. The test is performed for a list of
P value and O/E ratio thresholds, and finally the threshold combination that
minimizes FDR is chosen. This FDR analysis is also included in the MMRA
pipeline available online. Interestingly this FDR computation controls also possible
biases due to the presence of databases containing larger target lists. In fact, if this
kind of bias exists, it will also affect the random null model. Therefore, thresholds
that minimize the FDR also minimize the possible bias consequences. The FDR
values obtained for each classifier and for each threshold combination are reported
in Supplementary Table 6. Indeed, the three classifiers required different thresholds
to minimize FDR. P value thresholds: 0.001 for CRCA, 0.01 for CCMS and 0.001
for CCS; O/E thresholds: 1.5 for CRCA, 1.5 for CCMS and 2.5 for CCS.
MMRA step 3–network analysis. Network analysis was performed using
the ARACNE information-theoretic algorithm for inferring transcriptional
interactions11. The software was downloaded (http://wiki.c2b2.columbia.edu/
califanolab/index.php/Software/ARACNE) and included in the pipeline to infer
interactions between each microRNA selected by the previous steps and any
mRNA from the paired data set. Indeed, ARACNE is typically employed to
reconstruct extended networks with more than one ‘marker’ hub, while in our
analysis, having only one hub, we could in principle apply a simple miRNA-gene
MI-based analysis. However, such analysis would yield links between the
microRNA and all the expressed genes. An important issue would then be how to
filter the links, possibly in a more refined way than just by MI thresholding. We
solved this problem using the two main filtering procedures implemented in the
ARACNE algorithm: (i) estimate of MI significance trough the reconstruction
of a null model by sample reshuffling independently for each row (gene), and
(ii) bootstrapping procedure, with random exclusion of a subset of samples, to
generate a consensus network including edges supported across many bootstrap
networks. Edge support significance is then estimated by randomly shuffling the
edge positions, to create a null model of network consensus. For each microRNA
selected at the previous steps, data preparation for ARACNE involved the setting
up of an expression matrix (X) row-wise combining the entire mRNA expression
TCGA data set with the expression values of the single microRNA under analysis.
To generate a matrix compatible with the standard ARACNE pre-processing steps,
we inverted log2 transformation of the expression data set: naming Xij the elements
of the above-described expression matrix, we obtained the called ‘linear expression
matrix’ Y through the following operation Yij¼ 2Xij. Then, standard ARACNE
pre-processing involves quantile normalization of the data set Y, log2
transformation and filtering of those genes with a s.d. o1.2. For MMRA the only
edges of interest are those connecting the microRNA to mRNAs, therefore the
algorithm is run imposing the microRNA as the only hub of the network. The
chosen MI P value significance threshold (10 7) and bootstrapping P value
threshold (10 12 after 100 bootstrapped networks) are the originally
recommended ones54. Subsequently, each of the consensus networks constructed
around the selected microRNAs (the ‘regulons’), is tested for significant enrichment
in subtype signature genes respect to a random null model. To this end the master
regulator analysis (MRA) algorithm is used, as previously described12,18, to
evaluate the statistical significance (P values computed by Fisher’s exact test) of
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the overlap between the ‘regulon’ of each microRNA and the gene signature of the
subtype in which the microRNA was identified as differentially expressed at the
previous steps. To assess the sensitivity and specificity of our approach, we
compared our results with a null model constituted of the networks centred in
microRNAs that were expressed (detected in more than 45 of the 450 samples) but
not differential in any subtype of any classifier (signal-to-noise ratio, corresponding
to FC divided by within-group standard deviation, o 0.05). The regulons of the
microRNAs constituting the null model were also required to have an intersection
with any regulon of the previously selected candidate microRNAs o70%. We
obtained, in this way, a null model constituted of nine microRNAs and their
regulons. Then, we estimated the threshold for the MRA P value comparing the P
values obtained in our analysis with those of the null model. In detail, we
performed MRA also on the nine null model regulons, testing the enrichment in
signature genes of all the CRC subtypes. Then, from the P value distribution of the
null model we chose a threshold for the MRA of P¼ 10 4, corresponding to the
95th percentile of the null model. At the end of this step all the microRNAs having
a MRA P value in their associated subtype 410 4 were filtered out. To test, for
some microRNAs, if signature genes were not only enriched in the microRNA
regulons but also, within the regulons, were among those with the highest MI
content we used Preranked GSEA21. mRNAs contained in the regulon were ranked
according to their MI values. Then with Preranked GSEA we tested if signature
genes where significantly associated to high/low values of MI or they were
randomly distributed.
MMRA step 4–SLR analysis. In this step, to filter out weak microRNA–mRNA
relations within the regulons, MMRA employs SLR, a procedure previously
adopted for transcription factor/target analysis12,18. The assumption at the basis
of SLR application in such case was that the logarithm of a target mRNA
expression level is a linear function of the logarithm of the expression level of
its putative transcription factor regulator(s). We considered that such first-order
approximation is widely used also to model mRNA–microRNA interactions
(see for instance ref. 55); therefore SLR could also be applied in a case where
the regulators are microRNAs. SLR was performed employing together all the
microRNAs selected across the previous steps, against all gene signatures of all
three classifiers, without making any distinction between microRNAs identified for
one or another classifier. The SLR procedure involved the construction of a linear
model for each signature gene, as follows: the log2-expression level of the gene was
considered the response variable, and the log2-expression levels of microRNAs
linked by ARACNE to the gene were considered as the explanatory variables. Then
a stepwise algorithm is used to select the best minimal set of explanatory variables
within the model. Akaike information criterion was used as the stop criterion. The
output of SLR was reorganized at the microRNA level, to include, for each
microRNA, a list of response variables (subtype signature genes associated by
ARACNE) to which it was associated by SLR. The extent of modulation of a given
subtype by a given microRNA can then be estimated as the fraction of signature
genes for that subtype (UP or DOWN) whose expression is approximated by the
microRNA according to SLR analysis (positive or negative coefficient). To estimate
a significance threshold for this step we considered the distribution of the results
for all the selected microRNAs in all the CRC subtypes. These results are expected
to include a small subset of true associations, also selected across the previous steps,
and a larger set of random associations. We therefore selected the 90th percentile of
the fraction values, corresponding to a threshold of 13% of associated signature
genes. To generate the final output of the MMRA pipeline, significant fractions of
associated subtype genes are provided only for the microRNA-subtype associations
also selected in the previous steps.
Paired cell line expression data assembly and classification. For 18 CRC cell
lines, obtained as described19, microRNA expression profiling was obtained by
Illumina TruSeq Small RNA sequencing on the Illumina HiSeq 2000 platform. All
cell lines were maintained in their original culturing conditions according with
supplier guidelines. Cells were ordinarily supplemented with FBS at different
concentrations, 2mM L-glutamine, antibiotics (100Uml 1 penicillin and
100mgml 1 streptomycin) and grown in a 13 37 C and 5% CO2 air incubator.
Cells were routinely screened for absence of mycoplasma contamination using the
Venor GeM Classic kit (Minerva biolabs). The identity of each cell line was checked
by Cell ID System and by Gene Print 10 System (Promega), throught short tandem
repeats (STR) at 10 different loci (D5S818, D13S317, D7S820, D16S539, D21S11,
vWA, TH01, TPOX, CSF1PO and amelogenin). Amplicons from multiplex PCRs
were separated by capillary electrophoresis (3730 DNA Analyzer, Applied
Biosystems) and analysed using GeneMapperID software from Life Technologies.
Resulting cell line STR profiles were cross-compared and matched with the
available STR repositories online databases. Raw data were analysed by Genomatix
according to its standard pipeline (‘myGenomatics’; www.genomatix.de). Read
counts provided by Genomatix were then normalized with Deseq56, which is
widely used and has overall good performances44. For the same cell lines,
normalized global mRNA expression profiles were extracted from the 151-cell lines
data set19 available at Gene expression Omnibus (data set GSE59857, samples:
GSM1448073, GSM1448118, GSM1448124, GSM1448132, GSM1448134,
GSM1448142, GSM1448143, GSM1448146, GSM1448147, GSM1448164,
GSM1448175, GSM1448176, GSM1448177, GSM1448179, GSM1448180,
GSM1448194, GSM1448195 and GSM1448212).
The joint mRNA–microRNA data set for these 18 CRC cell lines is available in
Bioconductor (http://www.bioconductor.org/packages/release/data/experiment/
html/CRCL18.html). The 18 cell line mRNA classification in molecular subtypes
was downloaded from Supplementary Table 2 in ref. 19, so that differential
microRNA expression across subtypes could be assessed also in cell lines.
Consolidation of microRNA-subtype associations. The consolidation was based
on two main criteria: (i) differential expression between cell lines of the target
subtype and other cell lines, with the same direction as found in TCGA data
analysis. In particular, the following FC thresholds were used: 1.321722 for CCMS,
1.237681 for CRCA and 1.521026 for CCS. These thresholds were chosen based on
a null model obtained performing the same analysis on 1,000 random sets of
microRNAs of the same size of the MMRA output (in this case n¼ 24), ad selecting
the 90th percentile of the FC distribution obtained in this null model; (ii) Fraction
of subtype signature genes whose expression is significantly correlated to the
miRNA across subtypes (absolute Spearman r40.9 and 0.829, respectively, for
CRCA and CCMS, corresponding to a P value o0.1; this analysis could not be
done for CCS due to poor reliability of correlation estimates across only three
subtypes). The fraction of signature genes with an expression pattern significantly
correlated to that of the microRNA that was considered significant is 5% in CCMS
and 10% in CRCA. Also these thresholds were estimated through a null model
constructed from 1,000 random sets of microRNAs of the same size of those
passing step 1, and calculating the 90th percentile of the distribution of the per-
centage of signature genes correlated with the microRNA.
Selection of microRNAs for functional validation. To prioritize microRNAs on
which to perform the functional validation, we added two criteria: (i) microRNAs
identified by the MMRA pipeline in more than one classifier; (ii) correlation
analysis as described in point (ii) above, but considering only the microRNA
targets in the signature and not all signature genes. We then selected those
microRNAs with a fraction of correlated genes higher in this analysis with respect
to the one performed considering all the genes of the signature. In total, four
microRNAs optimally fulfilled these criteria and were selected for further analysis:
miR-194, miR-200b, miR-203 and miR-429. Interestingly, all four microRNAs are
downregulated in the SSM subtype, and their targets within the SSM signature are
upregulated.
Selection of cell lines for functional validation. All four microRNAs selected for
functional validation had a higher expression in non-SSM CRC cell lines. In
principle, if they have a driver role, their downregulation in such cells should make
the transcriptome shift towards the stem subtype. We therefore selected, among the
18 CRC cell lines, those non-SSM in which at least one of the microRNAs was
expressed at higher levels than in SSM cell lines (log2 ratio 40). In addition,
candidate cell lines should also express, respect to SSM cells, lower levels of genes
belonging to the ‘SSM-UP’ signature (average log2 ratioo0). Such downregulation
should be further enhanced when considering microRNA target genes within the
signature. One cell line, NCIH508, was found to fulfil such criteria for all four
microRNAs. Cell line HT29 satisfied these criteria for three microRNAs (miR-194,
miR-200b and miR-429) and SW403 was selected for miR-429.
Transcriptional response to microRNA silencing experiments. Details about
cell transductions with microRNA-targeting constructs, and the expression profiles
obtained from transduced cells, are available in the GEO data set GSE59883. To
functionally verify whether the four microRNAs identified by MMRA modulate the
SSM phenotype, we assembled a ‘SSM-UP signature’ joining the CCMS4-UP,
CRCA5-UP and CCS3-UP signatures. Similarly, a ‘SSM-DOWN’ signature was
obtained joining the CCMS4-DOWN and CRCA5-DOWN signatures (CCS has no
CCS3-DOWN genes). Genes with differential expression between mirZIP-trans-
duced and scramble cells were identified through a combined FC and Student’s
t-test analysis (absolute FC 41.5 and t-test P value o0.05). To identify genes
whose differential expression was specifically due to microRNA downregulation,
we filtered out those genes satisfying the same criteria also between wild-type and
scramble-transduced cells. To test for enrichment of stem signature genes among
genes upregulated by mirZIP transduction, we performed Hypergeometric test with
a standard significance threshold of Po0.05. To verify whether cells change of
subtype after microRNA silencing, we assembled a data set composed of the 18
original CRC cell lines (non-normalized data from the above-described GSE59857,
samples) plus the mirZIP, scramble and WT lines (non-normalized expression
profiles from GSE59883, all samples). The obtained data set was Loess normalized.
Then to test whether cell lines change phenotype after microRNA silencing, we
applied NTP classification, using the SSM-UP and SSM-DOWN signatures as
centroids, to a series of data sets each composed of the 18 CRC lines plus one
mirZIP-transduced duplicate (averaged) at a time. Addition to the 18-panel of one
single cell at a time was chosen to minimize distortions during the data standar-
dization phase of NTP.
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